Last Updated: 31/01/2025
Creation of a novel CSP monoclonal antibody that inhibits sporozoite movement within the skin and establishment of a system to measure its effectiveness against endemic local strains in order to develop a vaccine to prevent malaria parasite infection
Objectives
*Original title and text were machine translated from Japanese.
The purpose of this study is to demonstrate that sporozoites moving within the skin are good targets for inhibitory antibodies by creating a new CSP monoclonal antibody and establishing an evaluation system.
Malaria is a parasitic disease that kills approximately 400,000 people annually, mainly in tropical regions. Malaria parasites (sporozoites), which are implanted into the skin when an infected mosquito sucks blood, actively move and travel through the bloodstream to reach and infect liver cells. Therefore, sporozoites are attracting attention as a target for infection prevention methods, but problems have become clear with the first malaria vaccine that targets the surface protein CSP, such as insufficient effectiveness in suppressing infection and severity. This year, the project will investigate the establishment of a new CSP monoclonal antibody and its effect on suppressing movement of sporozoites within the skin/liver chip, and its effect on suppressing infection. It will also proceed with analysis of CSP genetic polymorphisms in endemic areas.
Apr 2021 — Mar 2024
$223,547
Related Resources
